RVMD241220C70000
- 1.97
- 0.000.00%
Revolution Medicines Newsroom
BofA Securities Maintains Revolution Medicines(RVMD.US) With Buy Rating
J.P. Morgan Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $63
BofA Securities Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $80
Bank of America Securities Keeps Their Buy Rating on Revolution Medicines (RVMD)
A Quick Look at Today's Ratings for Revolution Medicines(RVMD.US), With a Forecast Between $63 to $72
Revolution Medicines Is Maintained at Overweight by Piper Sandler
Revolution Medicines Analyst Ratings
A Quick Look at Today's Ratings for Revolution Medicines(RVMD.US), With a Forecast Between $64 to $72
Analysts' Top Healthcare Picks: CVS Health (CVS), Revolution Medicines (RVMD)
Revolution Medicines: Strong Buy Rating Backed by Financial Stability and Promising Cancer Treatment Advances
H.C. Wainwright Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $62
Promising Clinical Trial Results and Strategic Combination Bolster Buy Rating for Revolution Medicines
TD Cowen Maintains Revolution Medicines(RVMD.US) With Buy Rating
Barclays Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $60
Guggenheim Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $82
Revolution Medicines Is Maintained at Outperform by Oppenheimer
Stifel Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $56
Oppenheimer Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $60
Needham Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $61
Needham Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $61